Samedan Ltd Pharmaceutical Publishers


Advanced search

Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online Conferences White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home > ebr > winter 2022 > ai does not drive novel drug discovery, science does

PUBLICATIONS

European Biopharmaceutical Review AI Does Not Drive Novel Drug Discovery, Science Does
The use of AI in drug discovery, or any industry, is not a futuristic concept. However, it continues to receive media attention and is pushed by industry voices as a revolutionary fix for declining productivity. This is a fundamental problem because AI’s buzzword factor has created a misunderstanding of its potential and the incorrect perception that it is ahead of its time. Nevertheless, people love a good innovation story. To help put AI into perspective, a useful example is the recent automotive industry shake-up. For almost a decade, Tesla dominated headlines for pioneering electric vehicles and self-driving cars, creating an almost unobtainable futuristic aura. Many auto manufacturers dismissed this disruption and carried on producing gas-powered vehicles with only incremental innovation. We are quickly seeing that the future is progressively becoming more technology-enabled, and the rise of electric-powered vehicles is no exception. Those that are unwilling to change will not succeed. Moreover, those that were slow to change are now behind the market. Despite the hype, Tesla transformed the industry. Using that analogy, we can say the same for the implementation of AI in the pharmaceutical industry. It has been dismissed by some, but will soon catalyse wider disruption.
Read full article from PDF >>



Rate this article	You must be a member of the site to make a vote.	Average rating:	0

There are no comments in regards to this article.

Post a comment

Read all comments

Andrew Radin is the co-founder and Chief Executive Officer of Aria Pharmaceuticals, a preclinical-stage pharma company discovering and developing novel small-molecule therapies for complex and hard to treat diseases. Andrew created the company’s first drug development algorithms as part of his studies in biomedical informatics at Stanford University in 2014. Since co-founding Aria, Andrew was named an Emerging Pharma Leader by Pharma Executive magazine, was invited to give a TEDMED talk, and was named a Top 100 AI Leader by Deep Knowledge Analytics. Andrew studied Biomedical Informatics in Stanford University’s SCPD graduate programme (US) and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology, US.

Andrew Radin

Download
PDF file


Print this page	Send to a friend	Privacy Policy

Download Adobe Reader

News and Press Releases

Argonaut Manufacturing Services Set to Expand Drug Product Fill/Finish Capabilities with Significant Capital Investment

Carlsbad, CA, 10th January 2023 - Argonaut Manufacturing Services (‘Argonaut’), a contract manufacturing organization (CMO) serving the life sciences, molecular diagnostics, and biopharma industries, today announced a capital investment led by majority shareholder Telegraph Hill Partners that will be focused on expansion at their Carlsbad, CA, manufacturing facilities.
More info >>

All releases >>

White Papers

Using Device Strategy to Drive R&D Productivity

Phillips-Medisize

More info >>

All white papers >>

AI Does Not Drive Novel Drug Discovery, Science Does